[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100397798":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":42,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Milano Bicocca","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","intracranial pressure monitoring","Invasive monitoring of intracranial pressure by using CereLink monitor.",[14],{"name":15,"affiliation":5,"role":16},"Giuseppe Citerio, Professor","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":21,"email":22},"CONTACT","+39039233","4316","giuseppe.citerio@unimib.it",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Fondazione IRCCS San Gerardo dei Tintori","RECRUITING","Monza","MB","20900","Italy","IT",{"type":33,"coordinates":34},"Point",[35,36],9.27246,45.58005,{"lat":36,"lon":35},[39],{"name":40,"role":19,"phone":41,"phoneExt":7,"email":22},"Giuseppe Citerio, MD","+390392334316",{"type":43,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[45],{"name":46,"class":47},"Integra LifeSciences Corporation","INDUSTRY","100397798","intracranial-pressure-time-dose-impeto-100397798",false,"NCT04459806","Intracranial PrEssure Time dOse (ImPETO)","Evaluation of Intracranial Pressure Time Dose by the New Integra CereLink ICP Monitor","ImPETO","Inclusion Criteria:\n\n* Aged within 18 and 80 years;\n* Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;\n* ICP monitoring started for clinical indication and accordingly to local policies\n* ICP device connected to the Integra CereLink ICP monitor.\n\nExclusion Criteria:\n\n* ICP monitoring not inserted\n* No availability of the Integra CereLink ICP monitor.","ALL","18 Years","80 Years",{"count":60,"type":61},250,"ESTIMATED","OBSERVATIONAL","The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting.\n\nTherefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.",[65,66,67,68],"Intracranial Hypertension","Traumatic Brain Injury","Subarachnoid Hemorrhage","Intracranial Hemorrhages","2025-09-08",{"date":71,"type":72},"2025-09-15","ACTUAL",{"date":74,"type":72},"2023-11-13",{"date":76,"type":61},"2026-12-31",{"name":5,"class":6},1]